Ezutromid

• Description :

  Ezutromid is a first orally available drug for the treatment of Duchenne muscular dystrophy (DMD), a lethal, X-linked muscle wasting disease caused due to lack of dystrophin-a cytoskeleton protein. Ezutromid has shown potential as disease modifying treatment for DMD patients irrespective of their gene mutation. Ezutromid acts on utrophin modulation and has potential to slow down or stop the progression of DMD.

• Shipping Conditions :

  gel pack

• Storage Conditions :

  -20°C

• Shelf Life :

  36 months